Patents Assigned to Wyeth
  • SEROTONERGIC AGENTS
    Publication number: 20090215794
    Abstract: Novel piperazine derivatives are provided having the formula wherein R1 is cyano, nitro, trifluoromethyl or halogen, or pharmaceutically acceptable acid addition salts thereof, which are useful as 5-HT1A receptor antagonists.
    Type: Application
    Filed: May 5, 2009
    Publication date: August 27, 2009
    Applicant: Wyeth
    Inventors: Wayne E. Childers, Michael G. Kelly, Sharon J. Rosenzweig-Lipson
  • Process for the purification of substituted benzoxazole compounds
    Patent number: 7579478
    Abstract: The present invention provides processes for the purification of substituted benzoxazole compounds, and in particular 2-(3-fluoro-4-hydroxy-phenyl)-7-vinyl-benzooxazol-5-ol. The processes include recrystallizing the compound from a solution comprising acetone and acetonitrile; treating the crude purified product with a clarifying agent in a solution comprising ethyl acetate, and precipitating or triturating the compound from a mixed solvent system.
    Type: Grant
    Filed: March 6, 2006
    Date of Patent: August 25, 2009
    Assignee: Wyeth
    Inventor: Silvio Iera
  • Methods for Using Rapamycin Analogues in the Treatment of Neurological Disorders
    Publication number: 20090209527
    Abstract: The present invention provides methods for treatment of neurological disorders or complications due to stroke or head injury; benign or malignant neoplastic disease, carcinomas and adenocarcinomas; proliferative disorders; and inflammatory disorders, comprising administering a compound as described herein to a subject in need thereof, and a pharmaceutically acceptable carrier, within a therapeutic window that is from about 4 hours to 24 hours, or longer, for example at least 4, 6, 9, 12, 15, 18, 21 or 24 hours, or longer, after the onset of the neurological, proliferative, or inflammatory disorder or a symptom thereof.
    Type: Application
    Filed: February 19, 2009
    Publication date: August 20, 2009
    Applicant: Wyeth
    Inventors: Kevin Pong, Margaret Maria Zaleska
  • USE OF RXR AGONISTS FOR THE TREATMENT OF OSTEOARTHRITIS
    Publication number: 20090209601
    Abstract: Disclosed herein are methods of preventing and treating osteoarthritis through the use of RXR agonists.
    Type: Application
    Filed: February 11, 2009
    Publication date: August 20, 2009
    Applicant: Wyeth
    Inventors: Sunil Nagpal, Zhiyong Yang, Elisabeth Morris, Edward R. Lavallie, Lisa A. Collins-Racie
  • SUBSTANTIALLY PURE GLYCOPEPTIDE ANTIBIOTICS AC-98-1; AC-98-2; AC-98-3; AC-98-4 AND AC-98-5
    Publication number: 20090209452
    Abstract: The invention provides new substantially pure antibiotics designated AC-98-1, AC-98-2, AC-98-3, AC-98-4 and AC-98-5 derived from the microorganism Streptomyces hygroscopicus.
    Type: Application
    Filed: December 13, 2006
    Publication date: August 20, 2009
    Applicant: Wyeth Holdings Corporation
    Inventors: Guy Thomas Carter, Haiyin He
  • Avian vaccine for protection against colibacillosis
    Patent number: 7575754
    Abstract: A genetic deletion mutant live E. coli vaccine suitable for mass application to poultry, including chickens, is provided. Also provided is a safe and effective method to protect poultry against the ravages of Escherichia coli bacillosis infection and disease in which a live mutant aroA-gene deleted E. coli immunogen is administered to chickens, turkeys and the like via mass application routes such as coarse sprays and drinking water.
    Type: Grant
    Filed: March 7, 2008
    Date of Patent: August 18, 2009
    Assignee: Wyeth
    Inventors: Henry H. Fan, Mahesh Kumar, Roberto Marcello La Ragione, Martin John Woodward
  • Heterocyclyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands
    Patent number: 7576087
    Abstract: The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor.
    Type: Grant
    Filed: June 19, 2007
    Date of Patent: August 18, 2009
    Assignee: Wyeth
    Inventors: Ronald Charles Bernotas, Yinfa Yan
  • Quinolines and pharmaceutical compositions thereof
    Patent number: 7576215
    Abstract: This invention provides compounds of formula I that are useful in the treatment or inhibition of LXR mediated diseases.
    Type: Grant
    Filed: December 10, 2004
    Date of Patent: August 18, 2009
    Assignee: Wyeth
    Inventors: Michael D. Collini, Robert R. Singhaus, Jr., Baihua Hu, James W. Jetter, Robert L. Morris, David H. Kaufman, Christopher P. Miller, John W. Ullrich, Rayomand J. Unwalla, Jay E. Wrobel, Elaine Quinet, Ponnal Nambi, Ronald C. Bernotas, Merle Elloso
  • Alkynyl-containing tryptophan derivative inhibitors of TACE/matrix metalloproteinase
    Patent number: 7576222
    Abstract: This invention provides compounds of Formula I, having the structure: that are useful in treating diseases or disorders mediated by TNF-?. The invention further provides methods for use of the compounds for treating such a disease or disorder or for alleviating symptoms thereof.
    Type: Grant
    Filed: December 27, 2005
    Date of Patent: August 18, 2009
    Assignee: Wyeth
    Inventors: Kaapjoo Park, Jeremy I. Levin, Ariamala Gopalsamy
  • Novel immunogenic compositions for the prevention and treatment of meningococcal disease
    Publication number: 20090202593
    Abstract: The present invention relates to Neisseria ORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that immunospecifically bind to the foregoing and nucleic acid sequences encoding each of the foregoing, as well as the use of same in immunogenic compositions that are effective against infection by Neisseria meningitidis serogroup B.
    Type: Application
    Filed: June 16, 2008
    Publication date: August 13, 2009
    Applicant: Wyeth
    Inventors: Gary W. Zlotnick, Leah Diane Fletcher, John Erwin Farley, Liesel A. Bernfield, Robert J. Zagursky, Benjamin J. Metcalf
  • EXPRESSION OF ORPHAN GPR64 IN INFLAMMATORY DISEASES
    Publication number: 20090202474
    Abstract: Methods of screening for agents for treating inflammatory diseases are provided. The methods involve screening for agents that modulate the activity or expression of GPR64, which has been discovered herein to play a role in inflammatory diseases. Methods for treating an inflammatory disease, as well as methods of modulating the activity or expression of GPR64, methods of screening for an inflammatory disease in a subject, pharmaceutical compositions, a nucleic acid variant, and antibodies are also provided.
    Type: Application
    Filed: November 19, 2008
    Publication date: August 13, 2009
    Applicant: WYETH
    Inventors: Priya CHOCKALINGAM, Manas K. MAJUMDAR, Debra D. PITTMAN, Julia BILLIARD, Edward Roland LAVALLIE, Jeffrey L. FELDMAN, Lisa COLLINS-RACIE, Vishnuvardhan DAESETY, Robert MORAN, Elisabeth A. MORRIS, Paul YAWORSKY
  • Rapamycin Analogues and the Uses Thereof in the Treatment of Neurological Disorders
    Publication number: 20090203682
    Abstract: Method of treatment of neurological disorders or complications due to stroke or head injury through the administration of a pharmaceutical composition including a pharmaceutically acceptable excipient or carrier and a compound of formula I are provided:
    Type: Application
    Filed: November 24, 2008
    Publication date: August 13, 2009
    Applicant: Wyeth
    Inventors: Edmund Idris Graziani, Kevin Pong, Jerauld Skotnicki
  • Methods for minimizing thioamide impurities
    Patent number: 7572824
    Abstract: Methods for minimizing the formation of thioamide compounds using decoy agents during reactions, such as thionations of carbonyl compounds containing nitrile groups, and the products thereby are provided.
    Type: Grant
    Filed: November 16, 2007
    Date of Patent: August 11, 2009
    Assignee: Wyeth
    Inventor: Bogdan K. Wilk
  • Follistatin domain containing proteins
    Patent number: 7572763
    Abstract: The present invention relates to the use of proteins comprising at least one follistatin domain to modulate the level or activity of growth and differentiation factor-8 (GDF-8). More particularly, the invention relates to the use of proteins comprising at least one follistatin domain, excluding follistatin itself, for treating disorders that are related to modulation of the level or activity of GDF-8. The invention is useful for treating muscular diseases and disorders, particularly those in which an increase in muscle tissue would be therapeutically beneficial. The invention is also useful for treating diseases and disorders related to metabolism, adipose tissue, and bone degeneration.
    Type: Grant
    Filed: February 21, 2003
    Date of Patent: August 11, 2009
    Assignee: Wyeth
    Inventors: Jennifer J. Hill, Neil M. Wolfman
  • Metalloprotease activation of myostatin, and methods of modulating myostatin activity
    Patent number: 7572599
    Abstract: It has been determined that metalloprotease cleavage of a myostatin pro peptide results in activation of a latent inactive myostatin to an active form. Accordingly, methods of identifying agents that modulate metalloprotease mediated activation of myostatin are provided, as are agents identified using such methods. Also provided are methods of modulating muscle growth in an organism by increasing or decreasing metalloprotease mediated cleavage of a myostatin pro peptide.
    Type: Grant
    Filed: September 16, 2003
    Date of Patent: August 11, 2009
    Assignees: The Johns Hopkins University School of Medicine, Wisconsin Alumni Research Foundation, Wyeth
    Inventors: Se-Jin Lee, Alexandra C. McPherron, Daniel S. Greenspan, William N. Pappano, Neil Wolfman, Kathy Tomkinson
  • SUBSTITUTED BENZO[d][1,3]OXAZIN-2(4H)-ONES AND RELATED DERIVATIVES AND THEIR USES FOR MODULATING THE PROGESTERONE RECEPTOR
    Publication number: 20090197878
    Abstract: Compounds of formula (I), or pharmaceutically acceptable salts thereof, are provided, wherein R1-R6 and X are defined herein. Also provided are methods of preparing the compounds of formula (I), pharmaceutical compositions and kits containing a compound of formula (I), as are methods of treating endometriosis, hormone-dependent carcinomas, leiomyoma, fibroids, dysfunctional bleeding, polycystic ovary syndrome, and menopause related symptoms; methods of contraception; methods of providing hormone replacement therapy; methods of stimulating food intake; methods of synchronizing estrus; and methods of treating symptoms of premenstrual syndrome and premenstrual dysphoric disorder by administering to a mammal in need thereof a pharmaceutically effective amount of a compound of formula (I).
    Type: Application
    Filed: January 29, 2009
    Publication date: August 6, 2009
    Applicant: Wyeth
    Inventors: Thomas Joseph Commons, Douglas John Jenkins, Eugene John Trybulski, Andrew Fensome
  • Cyclothiocarbamate derivatives as progesterone receptor modulators
    Patent number: 7569564
    Abstract: Methods of using compounds which are progesterone receptor agonists for contraception and the treatment of progesterone-related maladies alone or in combination with an estrogen receptor agonist or progesterone receptor antagonist are provided. These compounds have the structure: wherein R1, R2, R3, R4, R5, and Q1 are defined herein.
    Type: Grant
    Filed: February 9, 2006
    Date of Patent: August 4, 2009
    Assignee: Wyeth
    Inventors: Puwen Zhang, Andrew Fensome, Eugene A. Terefenko, Lin Zhi, Todd K. Jones, James P. Edwards, Christopher M. Tegley, Jay E. Wrobel, Mark A. Collins
  • UspA2 nucleic acid of
    Patent number: 7569683
    Abstract: The present invention discloses the existence of two novel proteins UspA1 and UspA2, and their respective genes uspA1 and uspA2. Each protein encompasses a region that is conserved between the two proteins and comprises an epitope that is recognized by the MAb 17C7. One or more than one of these species may aggregate to form the very high molecular weight form (i.e. greater than 200 kDa) of the UspA antigen. Compositions and both diagnostic and therapeutic methods for the treatment and study of M. catarrhalis are disclosed.
    Type: Grant
    Filed: March 7, 2008
    Date of Patent: August 4, 2009
    Assignees: Board of Regents, The University of Texas System, Wyeth Holding Corporation
    Inventors: Eric J. Hansen, Christoph Aebi, Leslie D. Cope, Isobel Maciver, Michael J. Fiske, Ross A. Fredenburg
  • Isolated soluble IL-TIF/IL-22 receptor or binding protein which binds to IL-TIF/IL-22, and uses thereof
    Patent number: 7569667
    Abstract: The invention relates to soluble proteins which bind to the molecule known as IL-TIF/IL-22. The proteins can antagonize the effect of IL-TIF/IL-22 on target cells. The nucleic acid molecules encoding the proteins, and uses of the protein, are also described.
    Type: Grant
    Filed: May 4, 2006
    Date of Patent: August 4, 2009
    Assignee: Wyeth
    Inventors: Jean-Christophe Renauld, Laura Dumoutier
  • Tanaproget derivatives, metabolites, and uses thereof
    Patent number: 7569679
    Abstract: A method of generating synthetic metabolites of tanaproget derivatives thereof is provided. These compounds and methods of using these derivatives for detecting tanaproget metabolites in samples are provided.
    Type: Grant
    Filed: August 11, 2005
    Date of Patent: August 4, 2009
    Assignee: Wyeth
    Inventors: Li Shen, Kelly Keating, Oliver McConnell, William DeMaio, Appavu Chandrasekaran